Daiwa Securities Group Inc. Avrobio, Inc. Transaction History

Daiwa Securities Group Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 04, 2021	SELL	$12.79 - $17.1 $1,598 - $2,137	-125 Reduced 60.98%	80 $1,000
Q3 2020 Nov 02, 2020	BUY	$12.99 - $19.41 $337 - $504	26 Added 14.53%	205 $3,000
Q4 2019 Jan 31, 2020	SELL	$13.05 - $21.88 $300 - $503	-23 Reduced 11.39%	179 $4,000
Q3 2019 Nov 04, 2019	BUY	$14.12 - $23.44 $706 - $1,172	50 Added 32.89%	202 $3,000
Q1 2019 Apr 26, 2019	SELL	$12.46 - $22.05 $1,221 - $2,160	-98 Reduced 39.2%	152 $3,000
Q4 2018 Feb 05, 2019	BUY	$15.43 - $32.7 $3,857 - $8,175	250 New	250 $4,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.